Clinical Resources

Dosing tables by weight, professional publications using Mini-Infuser as part the methodology, and other technical materials

Dosing Tables by Weight

Ketamine at 3 micrograms/kg/minute See Table
Ketamine at 4 micrograms/kg/minute See Table 
Hydromorphone at 0.01 mg/kg/hr See Table


Chronic Pain and Ketamine

Maximize your clinic's impact on canine chronic pain with the Mini-Infuser drug delivery pump, providing precise ketamine infusions that target NMDA receptors to reverse central sensitization. This advanced system offers a transformative, multimodal solution for treating maladaptive pain and improving long-term quality of life for veterinary patients.

Dr. Lindsey Fry, DVM, cVMA, CCRP, CVPP A Novel Approach with a Familiar Tool—Part 1 Review of Ketamine and Chronic Pain Read Paper
Dr. Lindsey Fry, DVM, cVMA, CCRP, CVPP A Novel Approach with a Familiar Tool—Part 2 Clinical Application and Case Studies Read Paper
Dr. Lindsey Fry, DVM, cVMA, CCRP, CVPP Ketamine and Maladaptive Pain Watch Video

 

Acute Pain and Hydromorphone

The RxActuator Mini-Infuser® provides a solution for outpatient canine pain management by delivering a consistent 48-hour subcutaneous infusion of hydromorphone at therapeutic plasma levels. This wearable drug delivery pump ensures reliable, long-term analgesia for dogs, overcoming the limitations of traditional bolus dosing for chronic and moderate pain.

James S. Gaynor, DVM, MS, DACVAA, DAIPM The Perfect Pump: Wearable Pumps for Pain Control Read Paper
K. Messenger ; H. Enomoto ; H. Knych ; M. Papich Pharmacokinetics of Hydromorphone in Dogs after Intravenous Bolus and Delivered Subcutaneously with the RxActuator Mini-Infuser® Infusion Pump Read Paper
Kristen Messenger, Hiroko Enomoto, Melanie Madsen,
Heather Knych, and Mark Papich
Pharmacokinetics of Hydromorphone in
Dogs after Intravenous Bolus and Delivered Subcutaneously with the
RxActuator Mini-Infuser® Infusion pump
View Presentation

 

Anti Microbial Infusion with Ceftazidime

The RxActuator Mini-Infuser® ensures optimal therapeutic outcomes for time-dependent antimicrobials by delivering a continuous 48-hour subcutaneous infusion of ceftazidime in dogs, eliminating frequent, stressful injections while maintaining steady-state plasma concentrations essential for treating resistant canine bacterial infections.

Mark G. Papich DVM, MS, DACVCP Melanie Madsen DVM Kristen Messenger DVM, PhD, DACVAA, DACVCP Hiroko Enomoto DVM Ceftazidime pharmacokinetics in dogs after intravenous injection and delivered with the RxActuator Mini-Infuser infusion pump Read Paper